PDL BioPharma (PDLI) Misses Q3 EPS by 21c, Revenues Beat

PDL BioPharma (NASDAQ: PDLI) reported Q3 EPS of ($0.16), $0.21 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $44.2 million versus the consensus estimate of $33.86 million.

"Third quarter revenues exceeded $44 million driven by continued growth from the LENSAR Laser System and strong contributions from our royalty assets, both of which are tracking ahead of our previous guidance range," said Dominique Monnet, president and CEO of PDL. "LENSAR's quarterly revenues reached a record $8 million, up 22% over the prior-year period and up 27% year-to-date. Through PDL-funded R&D investments, LENSAR has continued to advance its best-in-class technology for the treatment of cataracts and the management of astigmatism. LENSAR's technology benefits have been increasingly recognized by ophthalmic surgeons, as indicated by steady and robust year-over-year procedure volume growth since the product was launched in mid-2012. Procedure volume for the first nine months of 2019 is on pace to continue this trend.

"We are also pleased with progress at Evofem Biosciences, which is on track to resubmit the Amphora® NDA in the fourth quarter," he added. "Given this timeframe, we anticipate Amphora's commercial launch for the prevention of pregnancy in 2020, subject to FDA approval. We believe our strategic investment in Evofem allows our shareholders to benefit from the significant near-term and longer-term commercial potential of Amphora. It may also present a strategic position for PDL's potential expansion into the underserved women's health market.

"We completed our $100 million share buy-back program during the third quarter, which represents the Company's largest single investment year-to-date. We are also continuing our efforts to reduce our operating expenses, with general and administrative expenses (G&A) down 16% year-to-date."

For earnings history and earnings-related data on PDL BioPharma (PDLI) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Sandisk targets mid-to-high teens revenue growth through FY2030
• Boxlight Corporation (BOXL) Tops Q2 EPS by 2050c